Effectiveness of a Novel Workplace-based Exercise Intervention: a Pilot Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03941145|
Recruitment Status : Completed
First Posted : May 7, 2019
Last Update Posted : March 24, 2020
|Condition or disease||Intervention/treatment||Phase|
|Health Behavior||Behavioral: Reduced-Exertion High-Intensity Interval Training (REHIT)||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||23 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||RCT|
|Masking:||None (Open Label)|
|Official Title:||Effectiveness of a Novel Workplace-based Exercise Intervention: a Pilot Study|
|Actual Study Start Date :||May 1, 2019|
|Actual Primary Completion Date :||September 13, 2019|
|Actual Study Completion Date :||November 13, 2019|
Participants allocated to the intervention group will be asked to perform 2 exercise sessions per week for 6 weeks. Each session will involve 10 min of low-intensity cycling (25 W) interspersed with two 20-s 'all-out' cycle sprints against a resistance equivalent to 5% of body mass. The exercise intervention will be delivered on a commercially available cycle ergometer with software developed by CAR.O.L.
Behavioral: Reduced-Exertion High-Intensity Interval Training (REHIT)
REHIT is a type of Sprint Interval Training (SIT) that has been shown to be efficacious at improving maximal aerobic capacity using a minimal volume of exercise.
No Intervention: Control
The effects of the intervention will be compared to a no-intervention control group recruited from the same workplace settings.
- Change in maximal aerobic capacity [ Time Frame: Change from baseline to 3 days after the 6-week intervention ]Aerobic capacity: a key risk factor of noncommunicable disease
- Change in motivation for exercise [ Time Frame: Change from baseline to 3 days after the 6-week intervention ]Motivation to exercise as assessed using the RM 4-FM questionnaire, a 16-item questionnaire assessing reasons for trying to be physically active on a scale from 1 ('not at all true') to 7 ('very true'). Higher scores indicate a greater motivation for performing exercise. Scores are added to get an overall score, with higher overall scores indicating greater intrinsic motivation.
- Change in health status [ Time Frame: Change from baseline to 3 days after the 6-week intervention ]Health status as assessed using the Short Form (36) Health Survey (SF36), which is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
- Change in perceived stress [ Time Frame: Change from baseline to 3 days after the 6-week intervention ]Perceived stress as assessed using the Perceived Stress Scale questionnaire, which measures the degree to which situations in one's life are appraised as stressful. The 10-item questionnaire ask for the frequency of stressful events in the last month, scored on a scale from 0 ('never') to 4 ('very often'). The sum score is taken, with higher scores indicating more perceived stress.
- Intervention acceptability [ Time Frame: 3 days after the 6-week intervention ]Intervention acceptability as assessed using a questionnaire published by Boereboom et al (2016). This 11-item questionnaire asks how strongly participants agree with statements on the acceptability of the exercise intervention on a scale from 1 ('strongly disagree') to 5 ('strongly agree').
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03941145
|Stirling, United Kingdom, FK49LA|